To describe the changes seen on bone scan and correlate them with changes in relative chemical biomarkers, patient's functional status and level of pain.
Study Type
OBSERVATIONAL
Enrollment
21
Previously known as Alpharadin, Radium-223 dichloride is a calcium-mimetic, alpha emitting radiopharmaceutical, which introduces double-stranded DNA breaks in metastatic cancer cells.
The University of Texas Health Science Center at Houston
Houston, Texas, United States
Change in number of osteoblastic bone lesions
number of lesions specified before and after the treatment with a bone scan
Time frame: Pretreatment (about 30 days before treatment) and post treatment (about 4 weeks after treatment)
functional status as indicated by score on the Eastern Cooperative Oncology Group (ECOG) performance scale
The ECOG scale describes a patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.). The possible scores on the scale are 0 to 5, with 0 being the best outcome and 5 being the worst outcome, details of each score are listed below. Grade 0 = Fully active, able to carry on all pre-disease performance without restriction Grade 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work Grade 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours Grade 3 = Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours Grade 4 = Completely disabled; cannot carry on any selfcare; totally confined to bed or chair Grade 5 = Dead
Time frame: Pretreatment (about 1 to 3 days before each treatment) for a total of 6 treatments
pain level as assessed by numeric rating score
As assessed using numeric rating score from 1-10 with 10 being the highest level of pain
Time frame: Pretreatment (about 1 to 3 days before each treatment) for a total of 6 treatments
(PSA) prostate specific antigen level
normal level should be 4.0 ng/mL. value is measured after each dose
Time frame: pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments
(ALP) alkaline phosphatase level
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The normal value for alkaline phosphatase is 53 to 128 U/L.
Time frame: pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments
Hemoglobin level
The normal level for males is 14 to 18 g/dl
Time frame: pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments
Platelet level
A normal platelet count ranges from 150,000 to 450,000 platelets
Time frame: pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments
Neutrophil count
The normal range for neutrophils is 2.5-7.5 x 10 9 /L
Time frame: pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments
Creatinine level
Normal levels of creatinine in the blood are approximately 0.6 to 1.2 milligrams (mg) per deciliter (dL)
Time frame: pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments
white blood cell count
The typical white blood cell count varies from 4,000 to 10,000 cells per mm3.
Time frame: pretreatment (about 1 to 7 days before each treatment) for a total of 6 treatments